Skip to main content

Treatment Clinical Trials for Osteosarcoma

Review the osteosarcoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-39 of 39

DFMO Maintenance for the Treatment of Patients with Relapsed Ewing Sarcoma or Osteosarcoma
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cabozantinib Plus High-Dose Ifosfamide for the Treatment of Relapsed or Refractory Ewing Sarcoma and Osteosarcoma, CaIRS Trial
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Status: Active
Location: 2 locations
A Study of EGFR806 CAR T-Cell Immunotherapy for Treating Children and Young Adults with Recurrent/Refractory Solid Tumors
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors
Status: Active
Location: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Upfront Surgical Resection for the Treatment of Localized High-Grade Osteosarcoma of the Extremity
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Status: Temporarily Closed to Accrual
Location: 26 locations
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults with Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
Status: Temporarily Closed to Accrual
Location: 6 locations
Targeted IL12 T-cell Therapy for Treatment Advanced or Metastatic Soft Tissue or Bone Sarcomas
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas